Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells
Open accessAbstract
Tumor Treating Fields (TTFields) are low intensity, intermediate frequency, alternating electric fields. TTFields are a unique anti-mitotic treatment modality delivered in a continuous, noninvasive manner to the region of a tumor. It was previously postulated that by exerting directional forces on highly polar intracellular elements during mitosis, TTFields could disrupt the normal assembly of spindle microtubules. However there is limited evidence directly linking TTFields to an effect on microtubules. Here we report that TTFields decrease the ratio between polymerized and total tubulin and prevent proper mitotic spindle assembly. The aberrant mitotic events induced by TTFields lead to abnormal chromosome segregation, cellular multinucleation and caspase dependent apoptosis of daughter cells. The effect of TTFields on cell viability and clonogenic survival substantially depends upon the cell division rate. We show that by extending the duration of exposure to TTFields, slowly dividing cells can be affected to a similar extent as rapidly dividing cells.
AI snapshot
Written from the paper’s full text.
TL;DR
TTFields (low-intensity, intermediate-frequency alternating electric fields) disrupt mitotic spindle microtubules, reduce polymerized tubulin, and cause chromosome missegregation, multinucleation, and caspase-dependent apoptosis in cancer cells. Treatment efficacy depends strongly on cell division rate, and extending exposure improves effects in slowly dividing cells.
Key findings
- TTFields decreased the polymerized-to-total tubulin ratio in A2780 ovarian carcinoma cells after 48 h at 200 kHz (12.8% decrease, p = 0.021), and increased depolymerized tubulin under rapid-turnover conditions after trypsinization/re-plating (p = 0.011); no significant change was seen at the slower-turnover 30-h time point.
- TTFields caused abnormal mitotic spindle geometry and multinucleation: in U-87 MG cells, abnormal cells with multiple nuclei/micronuclear structures increased from 2% to 8% after 72 h (P = 0.002), and in MSTO-211H mesothelioma cells from 1% to 18% after 150 kHz treatment (P < 0.0001).
- In Fischer rats with intracranial F-98 glioma, 7 days of 200 kHz TTFields at 200 V/m reduced tumor volume fold increase by 41% (p = 0.05; n = 14 treated vs n = 13 control) and significantly reduced normal metaphase and anaphase figures (p < 0.001 for both).
- Across ten solid-tumor cell lines, all showed reduced cell count and clonogenic survival after 72 h TTFields, but response did not correlate with model chromosome number; it did correlate with doubling time for cell count (Spearman r = 0.7939; p = 0.008) and clonogenic survival (r = 0.7212; p = 0.023). Longer exposure improved efficacy in A2780 (doubling time 18.7 h), U-87 MG (39 h), and AsPC-1 (54 h) cells.
Methods
- In vitro: multiple human cancer cell lines (e.g., A2780, A549, MDA-MB-231, U-87 MG, HeLa, MSTO-211H, AsPC-1) were treated with TTFields using the inovitro system at 175 V/m and cell-type-specific optimal frequencies; in vivo: F-98 glioma cells were implanted intracranially in Fischer rats and treated with 200 kHz TTFields at 200 V/m for 7 days, with tumor volume assessed by MRI and mitotic figures by H&E.
- Assays included confocal fluorescence microscopy of mitotic spindles, tubulin polymerization assays with Western blotting for α-tubulin, time-lapse video microscopy of HeLa cells expressing Tubulin-GFP, flow cytometry for cell cycle/Annexin V/PI/caspase activity, SKY and chromosome spreads, cell counts, clonogenic survival, and β-galactosidase senescence assays.
- Statistics used one-way ANOVA with Tukey’s test unless otherwise stated, and Spearman rank correlation for doubling time versus cell count/clonogenic survival.
Limitations
- Stated: whether TTFields directly interfere with tubulin subunit addition or destroy existing microtubules remains undetermined; higher-resolution studies are needed. The initial triggers of caspase-dependent apoptosis are not fully understood, and it remains unclear whether post-mitotic death is solely due to aneuploidy or also delayed damage from mitosis.
- Stated: the authors lack a clear explanation for divergent cell fates after TTFields exposure, and future randomized clinical trials are needed to confirm whether extended treatment duration improves clinical outcomes.
- Evident: most mechanistic data are from in vitro cancer cell lines, with only one rat glioma model; several results are reported as “data not shown,” and p53 status, SAC status, and apoptotic signaling differences are proposed but not resolved in this study.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 30 cited sources checked · 0 supported · 0 flagged
- Findingown data
Comparable results demonstrating enhanced efficacy achieved by increasing treatment duration were also obtained for AsPC-1 cell line.
“Comparable results demonstrating enhanced efficacy achieved by increasing treatment duration were also obtained for the AsPC-1 cell line (data not shown).”
Quote in the paperNot a substantial claim - Findingown data
There were no observed differences in total tubulin levels between control and TTFields treated cells.
“There were no observed differences in total tubulin levels between control and TTFields treated cells (data not shown).”
Quote in the paperSubstantial claim - Findingown data
Multinuclear progeny were formed in U-87 MG following 72 hours exposure to TTFields.
“Multinuclear progeny were also formed in U-87 MG following 72 hours exposure to TTFields.”
Quote in the paperSubstantial claim - Findingown data
One or both daughter cells underwent cell death (67% of mitotic cells) within 21.5 ± 19.4 hours following mitosis.
“Follow-up observations for the resulting progeny revealed that one or both daughter cells underwent cell death (67% of mitotic cells) within 21.5 ± 19.4 hours following mitosis (Supplementary Movie S2).”
Quote in the paperSubstantial claim - Findingown data
Giemsa staining analysis excluded the possibility of partial chromosomal loss.
“Of note, we also conducted Giemsa staining analysis, the results of which excluded the possibility of partial chromosomal loss (data not shown).”
Quote in the paperNot a substantial claim
- Findingown data
A significant positive Spearman rank correlation was found between treated cell doubling time and clonogenic survival following TTFields exposure (r = 0.7212; p = 0.023).
“A significant positive Spearman rank correlation was found between treated cell doubling time and both cell count (r = 0.7939; p = 0.008) and clonogenic survival (r = 0.7212; p = 0.023) following TTFields exposure (Fig. 3C).”
Quote in the paperSubstantial claim - Findingown data
A2780 cells treated with TTFields 6 hours after re-plating contained increased levels of depolymerized tubulin compared to untreated cells (p = 0.011).
“cells treated with TTFields 6 hours after re-plating, (a time point at which rapid microtubule turnover rates exist), contained increased levels of depolymerized tubulin compared to untreated cells (p = 0.011).”
Quote in the paperSubstantial claim - Findingown data
Cells treated with TTFields show a large variation in chromosomal counts.
“SKY analysis and chromosome spreads (metaphase spreads) were performed and these revealed that cells treated with TTFields show a large variation in chromosomal counts (Fig. 2E–H).”
Quote in the paperSubstantial claim - Findingown data
TTFields induce caspase dependent apoptosis of daughter cells.
“caspase dependent apoptosis of daughter cells”
- Also stated in: § TTFields Exposure Induces Caspase-Mediated Cell Death · boosted
“apoptosis was completely abrogated in the presence of Z-VAD-FMK confirming that TTFields induced cell death was caspase dependent”
Quote in the paperSubstantial claim - Also stated in: § TTFields Exposure Induces Caspase-Mediated Cell Death · boosted
- Findingown data
There is a dramatic increase in the number of hypodiploid cells, characterized by complete chromosomal loss, following TTFields treatment.
“There is a dramatic increase in the number of hypodiploid cells, characterized by complete chromosomal loss and this may provide a potential explanation to the observed increase in the percentage of resultant micronuclear structures.”
Quote in the paperSubstantial claim - Findingown data
No significant change in depolymerized tubulin was observed between untreated cells and cells treated with TTFields 30 hours after re-plating.
“No significant change was observed between untreated cells and cells that were treated with TTFields 30 hours after re-plating, a time point at which slower microtubule turnover rates prevail (data not shown).”
Quote in the paperNot a substantial claim - Findingown data
Formation of abnormal cells containing multiple nuclei and micronuclear structures increased from 2% to 8% following TTFields treatment in U-87 MG (P = 0.002).
“the formation of abnormal cells containing multiple nuclei and micronuclear structures was increased from 2% to 8% following TTFields treatment (P = 0.002).”
Quote in the paperSubstantial claim - Findingown data
Of total 75% failed cell divisions, 8% of deaths occurred while in mitosis.
“Of total 75% failed cell divisions, 8% of deaths occurred while in mitosis.”
Quote in the paperSubstantial claim - Findingown data
All tested cell lines demonstrated reduced clonogenic survival following 72 hours of TTFields treatment.
“All tested cell lines, demonstrated reduction in cell count (Fig. 3A) as well as reduced clonogenic survival (Fig. 3B) following the application of TTFields.”
Quote in the paperSubstantial claim - Findingown data
Hypodiploid malignant glioma cell lines U-87 MG and U-118 MG did not exhibit higher sensitivity to TTFields compared with cells with higher chromosome number at baseline e.g. A549.
“We observed that the hypodiploid malignant glioma cell lines U-87 MG and U-118 MG did not exhibit higher sensitivity to TTFields, as compared with cells with a higher chromosome number at baseline e.g. A549.”
Quote in the paperSubstantial claim - Findingown data
In cells exposed to TTFields, fluorescence intensity of tubulin between the two spindle poles is significantly decreased in both A549 and MDA-MB-231 cell lines.
“the fluorescence intensity of tubulin between the two spindle poles is significantly decreased in both cell lines”
Quote in the paperSubstantial claim - Findingown data
There was no evidence to suggest a difference in senescence phenotype between untreated and U-87 MG cells treated with TTFields for 24 or 120 hours.
“There was no evidence to suggest a difference in senescence phenotype between untreated and U-87 MG cells treated with TTFields for 24 or 120 hours (data not shown).”
Quote in the paperSubstantial claim - Findingown data
Increasing the duration of TTFields treatment improves cytotoxic effects in A2780 cells (doubling time 18.7 hours) as shown by decrease in both cell count and clonogenic survival.
“The results presented in Fig. 4A,B show that increasing the duration of treatment improves cytotoxic effects in A2780 cells (doubling time – 18.7 hours) as shown by a decrease in both cell count and clonogenic survival.”
Quote in the paperSubstantial claim - Findingown data
TTFields treatment results in a divergence from normal chromosome counts.
“TTFields Treatment Results in a Divergence from Normal Chromosomes Counts”
- Also stated in: § TTFields Treatment Results in a Divergence from Normal Chromosomes Counts · plain
“cells treated with TTFields show a large variation in chromosomal counts”
Quote in the paperSubstantial claim - Also stated in: § TTFields Treatment Results in a Divergence from Normal Chromosomes Counts · plain
- Findingown data
TTFields induce cellular multinucleation.
“cellular multinucleation”
- Also stated in: § TTFields Treatment Results in the Formation of Multiple Nuclei within Cancer Cells · plain
“the formation of abnormal cells containing multiple nuclei and micronuclear structures was increased from 2% to 8% following TTFields treatment (P = 0.002).”
Quote in the paperSubstantial claim - Also stated in: § TTFields Treatment Results in the Formation of Multiple Nuclei within Cancer Cells · plain
- Findingown data
TTFields treated A2780 cells contained decreased levels of polymerized microtubules compared to untreated cells (12.8%, p = 0.021) after 48 hours of 200 kHz TTFields.
“Immunoblotting for α-tubulin revealed that TTFields treated cells contained decreased levels of polymerized microtubules compared to untreated cells (12.8%, p = 0.021; Fig. 1F,G).”
Quote in the paperSubstantial claim - Findingown data
Number of A2780 cells accumulating in M-phase significantly increased from baseline following exposure to TTFields.
“The results in Fig. 5E showed that the number of A2780 cells accumulating in M-phase significantly increased from baseline following exposure to TTFields, similar to our time-lapse observations from HeLa cells.”
Quote in the paperSubstantial claim - Findingown data
A2780 cells exposed to TTFields exhibited accumulation in G2/M (32.0 ± 2.6% after 72 hours treatment relative to 23.0 ± 0.9% in control, p < 0.01).
“The results in Fig. 5D, demonstrated that A2780 cells exposed to TTFields exhibited accumulation in G2/M (32.0 ± 2.6% after 72 hours treatment relative to 23.0 ± 0.9% in control, p < 0.01).”
Quote in the paperSubstantial claim - Findingown data
TTFields prevent proper mitotic spindle assembly.
“prevent proper mitotic spindle assembly”
- Also stated in: § TTFields Interfere With Mitotic Spindle Structure · hedged
“cells treated with TTFields show abnormal spindle geometry suggesting that TTFields hamper normal spindle organization”
- Also stated in: § Discussion · plain
“specific effects on spindle assembly in replicating cells”
Quote in the paperSubstantial claim - Also stated in: § TTFields Interfere With Mitotic Spindle Structure · hedged
- Findingown data
All tested cell lines demonstrated reduction in cell count following 72 hours of TTFields treatment.
“All tested cell lines, demonstrated reduction in cell count (Fig. 3A) as well as reduced clonogenic survival (Fig. 3B) following the application of TTFields.”
Quote in the paperSubstantial claim - Findingown data
U-87 MG cell accumulation was observed to peak in G1 phase at 48 hours.
“In contrast, U-87 MG cell accumulation was observed to peak in G1 phase at 48 hours (data not shown).”
Quote in the paperNot a substantial claim - Findingown data
When treated with TTFields, A549 and MDA-MB-231 cells exhibit severe structural mitotic spindle deformities.
“when treated with TTFields, A549 and MDA-MB-231 cells exhibit severe structural mitotic spindle deformities.”
Quote in the paperSubstantial claim - Findingown data
In Fischer rats inoculated intracranially with F-98 glioma cells, tumor volume fold increase was reduced by 41% (p = 0.05) following TTFields application (n = 14) compared to control (n = 13).
“We found that tumor volume fold increase was reduced by 41% (p = 0.05; Student’s t test) following TTFields application (n = 14) as compared to the control (n = 13), similar to the results previously published by Kirson et al.6.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Kirson et al.
Not checked in the free run.
- Findingown data
A significant positive Spearman rank correlation was found between treated cell doubling time and cell count following TTFields exposure (r = 0.7939; p = 0.008).
“A significant positive Spearman rank correlation was found between treated cell doubling time and both cell count (r = 0.7939; p = 0.008) and clonogenic survival (r = 0.7212; p = 0.023) following TTFields exposure (Fig. 3C).”
Quote in the paperSubstantial claim - Findingown data
TTFields decrease the ratio between polymerized and total tubulin.
“Here we report that TTFields decrease the ratio between polymerized and total tubulin, and prevent proper mitotic spindle assembly.”
- Also stated in: § TTFields Interfere With Mitotic Spindle Structure · boosted
“Taken together, these results demonstrate that under rapid turnover conditions, TTFields decrease the ratio of polymerized to total tubulin, thus providing a putative explanation for the disruption of the mitotic spindle assembly apparatus.”
Quote in the paperSubstantial claim - Also stated in: § TTFields Interfere With Mitotic Spindle Structure · boosted
- Findingreasoning
TTFields induce abnormal chromosome segregation.
“The aberrant mitotic events induced by TTFields lead to abnormal chromosome segregation”
- Also stated in: § TTFields Treatment Results in a Divergence from Normal Chromosomes Counts · plain
“cells treated with TTFields show a large variation in chromosomal counts”
Quote in the paperSubstantial claim - Also stated in: § TTFields Treatment Results in a Divergence from Normal Chromosomes Counts · plain
- Findingown data
TTFields treatment results in formation of multiple nuclei within cancer cells.
“TTFields Treatment Results in the Formation of Multiple Nuclei within Cancer Cells”
- Also stated in: § TTFields Treatment Results in the Formation of Multiple Nuclei within Cancer Cells · boosted
“long-term live cell imaging clearly revealed the disruption of the spindle structure followed by the formation of binucleate or polynucleate progeny (Fig. 2A, Supplementary Movie S1).”
Quote in the paperSubstantial claim - Also stated in: § TTFields Treatment Results in the Formation of Multiple Nuclei within Cancer Cells · boosted
- Findingown data
There was no clear correlation between model chromosome number and clonogenic survival following TTFields.
“However, there was no clear correlation between model chromosome number and clonogenic survival (Spearman rank correlation coefficient, data not shown).”
Quote in the paperSubstantial claim - Findingown data
Comparable chromosome count variation results were obtained in U-87 MG and AsPC-1 pancreatic adenocarcinoma cell lines following 150 kHz TTFields treatment.
“Comparable results were also obtained in U-87 MG (Supplementary Figure S2) and AsPC-1 pancreatic adenocarcinoma cell lines following 150 kHz TTFields treatment (Supplementary Figure S2).”
Quote in the paperNot a substantial claim - Findingown data
The effect of TTFields on cell viability and clonogenic survival substantially depends upon the cell division rate.
“The effect of TTFields on cell viability and clonogenic survival substantially depends upon the cell division rate.”
- Also stated in: § Variations in Response to TTFields are Independent of Model Chromosome Number and can be Explained by Differences in Cell Doubling Time · plain
“A significant positive Spearman rank correlation was found between treated cell doubling time and both cell count (r = 0.7939; p = 0.008) and clonogenic survival (r = 0.7212; p = 0.023) following TTFields exposure (Fig. 3C).”
Quote in the paperSubstantial claim - Also stated in: § Variations in Response to TTFields are Independent of Model Chromosome Number and can be Explained by Differences in Cell Doubling Time · plain
- Findingown data
TTFields treated HeLa cells exhibited a significant yet short increase in mitotic duration compared to controls (132.4 ± 60.8 vs 86.7 ± 51.1 minutes, p < 0.001).
“Results demonstrated that TTFields treated cells exhibited a significant yet short increase in mitotic duration as compared to controls (132.4 ± 60.8, 86.7 ± 51.1 minutes, respectively, p < 0.001) (Fig. 5A–C).”
Quote in the paperNot a substantial claim - Findingown data
Formation of abnormal cells containing multiple nuclei increased from 1% to 18% following 150 kHz TTFields treatment in MSTO-211H mesothelioma cells (P < 0.0001).
“formation of abnormal cells containing multiple nuclei was increased from 1% to 18% following 150 kHz TTFields treatment (P < 0.0001) (Supplementary Figure S2).”
Quote in the paperSubstantial claim - Findingown data
A significant reduction (p < 0.02) in mitotic rate was observed in rat F98 glioma model following 7 days of treatment with TTFields.
“a significant reduction (p < 0.02) in the mitotic rate was also observed in the rat F98 glioma model following 7 days of treatment with TTFields (Fig. 5F).”
Quote in the paperNot a substantial claim - Findingown data
For longer treatment periods, the decrease in percentage of viable cells was greater than that achieved with short treatment periods followed by longer observation timeframes.
“The results in Supplementary Figure S3 demonstrate that for longer treatment periods the decrease in the percentage of viable cells was greater than that achieved with short treatment periods followed by longer observation timeframes.”
Quote in the paperSubstantial claim - Findingown data
Percentage of cells undergoing early and late apoptosis dramatically increased following TTFields treatment.
“The results in Fig. 6A–C demonstrate that the percentage of cells undergoing early and late apoptosis dramatically increased following TTFields treatment.”
Quote in the paperSubstantial claim - Findingown data
Apoptosis was completely abrogated in presence of Z-VAD-FMK, confirming TTFields induced cell death was caspase dependent.
“Of significance, apoptosis was completely abrogated in the presence of Z-VAD-FMK confirming that TTFields induced cell death was caspase dependent (Fig. 6F).”
Quote in the paperSubstantial claim - Findingown data
Treatment of cells with caspase inhibitor Z-VAD-FMK severely impaired cytotoxicity induced by TTFields treatment.
“Treatment of cells with the caspase inhibitor severely impaired cytotoxicity induced by TTFields treatment.”
Quote in the paperSubstantial claim - Findingown data
TTFields exposure induces caspase-mediated cell death.
“TTFields Exposure Induces Caspase-Mediated Cell Death”
- Also stated in: § TTFields Exposure Induces Caspase-Mediated Cell Death · boosted
“apoptosis was completely abrogated in the presence of Z-VAD-FMK confirming that TTFields induced cell death was caspase dependent”
Quote in the paperSubstantial claim - Also stated in: § TTFields Exposure Induces Caspase-Mediated Cell Death · boosted
- Findingown data
TTFields-induced cell death occurs several hours following completion of mitosis.
“Our results suggest that TTFields induced cell death occurs several hours following completion of mitosis.”
Quote in the paperSubstantial claim - Findingown data
There was no evidence to suggest exposure to TTFields promoted cellular senescence following 48 hours of TTFields treatment in AsPC-1, H-1299, MCF-7, MDA-MB-231, A2780, and A549 cells.
“There was no evidence to suggest exposure to TTFields promoted cellular senescence following 48 hours of TTFields treatment in these cell lines (data not shown).”
Quote in the paperNot a substantial claim - Findingown data
Treatment of A2780 cells with TTFields led to a 1.9 fold increase in caspase activity after 48 hours.
“Compared with control cells, treatment of A2780 cells with TTFields led to a 1.9 fold increase in caspase activity (Fig. 6D).”
Quote in the paperSubstantial claim - Interpretationown data
By extending the duration of exposure to TTFields, slowly dividing cells can be affected to a similar extent as rapidly dividing cells.
“We show that by extending the duration of exposure to TTFields, slowly dividing cells can be affected to a similar extent as rapidly dividing cells.”
- Also stated in: § TTFields Efficacy can be Enhanced by Extending Treatment Duration · plain
“A longer period of exposure to TTFields resulted in a significant decrease in both cell count and clonogenic survival in U-87 MG cells (Fig. 4C,D).”
Quote in the paperSubstantial claim - Also stated in: § TTFields Efficacy can be Enhanced by Extending Treatment Duration · plain
- Interpretationreasoning
TTFields treatment exclusively affects dividing cells.
“Overall, these results reinforce our hypothesis that TTFields treatment exclusively affects dividing cells.”
Quote in the paperSubstantial claim - Interpretationown data
There is no correlation between pre-treatment karyotype and treatment outcome.
“Based on these data, we concluded that there is no correlation between pre-treatment karyotype and treatment outcome.”
Quote in the paperSubstantial claim - Interpretationreasoning
TTFields treatment efficacy is amplified when cells undergo additional mitosis during treatment exposure.
“These observations are consistent with the effect of TTFields on the mitotic spindle and suggest that TTFields treatment efficacy is amplified when cells undergo additional mitosis during treatment exposure.”
Quote in the paperSubstantial claim - Premisecitation
Chromosome missegregation can also be an inhibitor of tumorigenesis.
“However, there is now an expanding body of evidence suggesting that chromosome missegregation can also be an inhibitor of tumorigenesis56585960.”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [56] Holland, A. J. & Cleveland, D. W. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat. Rev. Mol. Cell Biol. 10, 478–487 (2009). source
Not checked in the free run.
- cites [58] Orticello, M. et al. N-terminus-modified Hec1 suppresses tumour growth by interfering with kinetochore-microtubule dynamics. Oncogene 34, 3325–3335 (2015). source
Not checked in the free run.
- cites [59] Weaver, B. A. et al. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11, 25–36 (2007). source
Not checked in the free run.
- Premisecitation
Clinical response to taxanes, which also target mitotic cells, does not correlate with tumor proliferation rate.
“as clinical response to taxanes, for example, which also target mitotic cells, does not correlate with tumor proliferation rate66.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [66] Noguchi, S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 97, 813–820 (2006). source
Not checked in the free run.
- Interpretationreasoning
A post-mitotic response involving activation of the p53 pathway is more likely than alternative explanations for TTFields-induced cell death.
“Thus, a post mitotic response which involves activation of the p53 pathway is more likely6162.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [61] Thompson, S. L. & Compton, D. A. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J. Cell Biol. 188, 369–381 (2010). source
Not checked in the free run.
- cites [62] Li, M. et al. The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc. Natl. Acad. Sci. USA 107, 14188–14193 (2010). source
Not checked in the free run.
- Interpretationown data
TTFields destabilize microtubules.
“We show for the first time, to our knowledge, that TTFields destabilize microtubules.”
Quote in the paperSubstantial claim - Interpretationown data
Data strongly suggest that, in addition to mitotic arrest, an accumulation of massive aneuploidy contributes to compromised viability following TTFields treatment.
“Although the initial triggers of caspase dependent apoptosis that arise following TTFields treatment are not fully understood, our data strongly suggest that, in addition to mitotic arrest, an accumulation of massive aneuploidy contributes to this compromised viability.”
Quote in the paperSubstantial claim - Premisecitation
A microtubule-targeting modality can lead to aneuploidy and subsequent cell death.
“The notion that a microtubule- targeting modality can lead to aneuploidy and subsequent cell death is supported by recent results by Zasadil et al. demonstrating that paclitaxel treatment leads to cell death in patients by inducing chromosome missegregation without mitotic arrest53.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Zasadil et al.
Not checked in the free run.
- Interpretationcitation
There may be additive efficacy in combining TTFields with spindle poisons.
“These conflicting observations suggest that there may be additive efficacy in combining TTFields with spindle poisons, a notion which is supported by clinical observations in which the combination of vinorelbine with paclitaxel in metastatic breast cancer patients has been associated with superior antitumoral activity50.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [31] Giladi, M. et al. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin. Oncol. 41 Suppl 6, S35–41 (2014). source
Not checked in the free run.
- cites [49] Kirson, E. D. et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med. Phys. 9, 1 (2009). source
Not checked in the free run.
- cites [50] Romero Acuna, L. et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J. Clin. Oncol. 17, 74–81 (1999). source
Not checked in the free run.
- Interpretationown data
There is probably more than a singular cell fate following TTFields exposure.
“In totality, these results suggest there is probably more than a singular cell fate following TTFields exposure.”
- Also stated in: § Discussion · hedged
“In addition, our time lapse microscopy and cell cycle data suggest that there is probably more than a singular cell fate following TTFields exposure.”
Quote in the paperSubstantial claim - Also stated in: § Discussion · hedged
- Premisecitation
Overall survival outcomes are more favorable in patients with recurrent glioblastoma who maintain higher therapeutic compliance with TTFields therapy.
“This conclusion is supported by clinical observations where overall survival outcomes are more favorable in those patients with recurrent glioblastoma who maintain higher therapeutic compliance with TTFields therapy10.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [10] Mrugala, M. M. et al. Clinical Practice Experience With NovoTTF-100A System for Glioblastoma: The Patient Registry Dataset (PRiDe). Semin. Oncol. 41 Suppl 6, S4–S13 (2014). source
Not checked in the free run.
- Interpretationcitation
Increased percentages of depolymerized tubulin in cells treated with TTFields while spreading following re-plating supports possibility that TTFields interfere with polymerization of microtubules.
“Increased percentages of depolymerized tubulin in cells treated with TTFields while spreading following re-plating supports the possibility that TTFields interfere with polymerization of microtubules42.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [42] Mooney, D. J. et al. Extracellular matrix controls tubulin monomer levels in hepatocytes by regulating protein turnover. Mol. Biol. Cell 5, 1281–1288 (1994). source
Not checked in the free run.
- May combine two claims. 18
- The quote only partly states this claim. 2
- Classified as probably not a substantial claim. 16
May combine two claims.
Findingown dataTTFields exposure causes both mitotic cell death and death in interphase.
“TTFields Exposure Cause Both Mitotic Cell Death and Death in Interphase”
- Also stated in: § TTFields Exposure Cause Both Mitotic Cell Death and Death in Interphase · hedged
“Overall, our data suggest that TTFields treated cells exhibit small delays in mitosis following which some cells die in mitosis while others eventually divide and continue to the next interphase.”
Quote in the paperSubstantial claim- Also stated in: § TTFields Exposure Cause Both Mitotic Cell Death and Death in Interphase · hedged
The quote only partly states this claim.
Findingown dataA longer period of exposure to TTFields resulted in a significant decrease in both cell count and clonogenic survival in U-87 MG cells (doubling time 39 hours).
“A longer period of exposure to TTFields resulted in a significant decrease in both cell count and clonogenic survival in U-87 MG cells (Fig. 4C,D).”
Quote in the paperSubstantial claimMay combine two claims. The quote only partly states this claim.
Findingown dataTime-lapse video microscopy revealed disruption of spindle structure followed by formation of binucleate or polynucleate progeny in HeLa cells expressing Tubulin-GFP exposed to 150 Hz TTFields.
“Time-lapse video microscopy was utilized to directly visualize spindle structure and nuclei in the daughter cells of HeLa cervix adenocarcinoma cells expressing Tubulin-GFP (green fluorescent protein) fusion protein while exposed to 150 Hz TTFields.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataExtension of TTFields treatment duration enhances treatment efficacy, as gradual decreases in both cell viability and clonogenic survival were observed as treatment continued.
“Extension of treatment duration proved to enhance treatment efficacy as gradual decreases in both cell viability and clonogenic survival were observed as treatment continued.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataWhile average cell count of A2780 cells treated with TTFields for 48 hours was 52 percent, in presence of Z-VAD-FMK cell count rose to 79 percent.
“While the average cell count of A2780 cells treated with TTFields for 48 hours was 52 percent, in the presence of Z-VAD- FMK cell count rose to 79 percent (Fig. 6E).”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataAlthough long-term effects of TTFields are maintained after a treatment break, extending the duration of TTFields application resulted in improved treatment outcomes.
“Therefore, although long-term effects of TTFields are maintained after a treatment break, extending the duration of TTFields application resulted in improved treatment outcomes.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataUnder rapid turnover conditions, TTFields decrease the ratio of polymerized to total tubulin, providing a putative explanation for disruption of the mitotic spindle assembly apparatus.
“Taken together, these results demonstrate that under rapid turnover conditions, TTFields decrease the ratio of polymerized to total tubulin, thus providing a putative explanation for the disruption of the mitotic spindle assembly apparatus.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Electric fields exert directional forces on polar intracellular elements such as organelles and macromolecules.
May combine two claims.
Interpretationown dataTTFields treatment results in nuclear aberrations including multinucleation, which is a sign of mitotic catastrophe.
“Taken together, these results suggest that TTFields treatment results in nuclear aberrations including multinucleation, which is a sign of mitotic catastrophe21.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataWithin any given treatment period, rapidly dividing cells are more likely to be affected by TTFields while non dividing cells remain intact.
“Together, these results demonstrate that within any given treatment period, rapidly dividing cells are more likely to be affected by TTFields while non dividing cells remain intact.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
PremisecitationLevels of aneuploidy elevated beyond a certain threshold suppress tumors by causing cell death.
“Silk et al. have recently suggested that levels of aneuploidy elevated beyond a certain threshold, suppress tumors by causing cell death46.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Silk et al.
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataDifferences within the range of 2-6% between the average resistivity and current density of the different media were measured and considered to be negligible.
“Differences within the range of 2-6% between the average resistivity and current density of the different media were measured and considered to be negligible.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningCells entering mitosis are those most likely to respond to TTFields because the mechanism of action involves disruption of spindle microtubules leading to mitotic catastrophe.
“As the mechanism of action of TTFields involves disruption of spindle microtubules, consequently leading to mitotic catastrophe, cells entering mitosis are those most likely to respond to TTFields.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationEffective doses of systemic drugs vary greatly and depend on pharmacokinetic and pharmacodynamic factors such as plasma concentration and elimination half-life.
“It should be acknowledged, however, that the effective doses of systemic drugs vary greatly and are dependent on pharmacokinetic and pharmacodynamic factors such as plasma concentration and elimination half life17.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [17] Gascoigne, K. E. & Taylor, S. S. How do anti-mitotic drugs kill cancer cells? J. Cell Sci. 122, 2579–2585 (2009). source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationMitotically arrested cells can escape mitosis to enter G1 phase as polyploid cells, in a process known as mitotic slippage.
“Alternatively mitotically arrested cells can escape mitosis to enter G1 phase as polyploid cells, in a process known as mitotic slippage262930.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [26] Rieder, C. L. & Maiato, H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 7, 637–651 (2004). source
Not checked in the free run.
- cites [29] Yamada, H. Y. & Gorbsky, G. J. Spindle checkpoint function and cellular sensitivity to antimitotic drugs. Mol. Cancer Ther. 5, 2963–2969 (2006). source
Not checked in the free run.
- cites [30] Elhajouji, A., Cunha, M. & Kirsch-Volders, M. Spindle poisons can induce polyploidy by mitotic slippage and micronucleate mononucleates in the cytokinesis-block assay. Mutagenesis 13, 193–198 (1998). source
Not checked in the free run.
Classified as probably not a substantial claim.
Study design and conductnone givenAtypical mitotic figures were determined in a blinded fashion based on intact or chromosome configurations during metaphase and anaphase.
“Atypical mitotic figures were determined in a blinded fashion based on intact or chromosome configurations during metaphase and anaphase.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductreasoningThe sham heat electrodes produced equal temperature changes to those produced by the field electrodes.
“The Sham heat electrodes produced equal temperature changes to those produced by the field electrodes by means of a heating resistor incorporated within them.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductnone givenControl rats were treated with sham electrodes geometrically matched to the TTFields group.
“Control rats were treated by means of sham electrodes which were geometrically matched to the TTFields group.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationMissegregation of chromosomes results in aneuploidy, which can lead to genomic instability and subsequent cell death or senescence in a process termed mitotic catastrophe.
“Missegregation of chromosomes results in aneuploidy, which can lead to genomic instability and subsequent cell death or senescence in a process termed mitotic catastrophe21.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [21] Vitale, I., Galluzzi, L., Castedo, M. & Kroemer, G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat. Rev. Mol. Cell Biol. 12, 385–392 (2011). source
Not checked in the free run.
May combine two claims.
Interpretationown dataWhile prolonged mitotic arrest can occur following TTFields exposure, cell death during subsequent interphase is more prevalent.
“While prolonged mitotic arrest can occur following TTFields exposure, cell death during the subsequent interphase is more prevalent.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
PremisecitationThe SAC is responsible for delaying the irreversible transition from metaphase to anaphase in order to avoid erroneous segregation of sister chromatids.
“The SAC, also known as the mitotic checkpoint, is responsible for delaying the irreversible transition from metaphase to anaphase in order to avoid erroneous segregation of sister chromatids222324.”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [22] Musacchio, A. & Hardwick, K. G. The spindle checkpoint: structural insights into dynamic signalling. Nat. Rev. Mol. Cell Biol. 3, 731–741 (2002). source
Not checked in the free run.
- cites [23] Musacchio, A. & Salmon, E. D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 8, 379–393 (2007). source
Not checked in the free run.
- cites [24] Weaver, B. A. & Cleveland, D. W. Decoding the links between mitosis, cancer and chemotherapy: The mitotic checkpoint, adaptation and cell death. Cancer Cell 8, 7–12 (2005). source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationCell death can also occur following cell division.
“In addition, cell death can also occur following cell division21.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [21] Vitale, I., Galluzzi, L., Castedo, M. & Kroemer, G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat. Rev. Mol. Cell Biol. 12, 385–392 (2011). source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationAnti-microtubule agents are thought to delay mitotic progression by activating the SAC, thereby inducing mitotic arrest and cell death directly from mitosis.
“Anti-microtubule agents are thought to delay mitotic progression by activating the SAC, thereby inducing mitotic arrest and cell death directly from mitosis24.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [24] Weaver, B. A. & Cleveland, D. W. Decoding the links between mitosis, cancer and chemotherapy: The mitotic checkpoint, adaptation and cell death. Cancer Cell 8, 7–12 (2005). source
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
Study design and conductnone givenAll available slides were reviewed by an independent pathologist, and average mitotic rate was blindly evaluated.
“All available slides were reviewed by independent pathologist (Ori Brenner, DACVP), and average mitotic rate was blindly evaluated.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataTTFields treated cells exhibit small delays in mitosis following which some cells die in mitosis while others eventually divide and continue to the next interphase.
“Overall, our data suggest that TTFields treated cells exhibit small delays in mitosis following which some cells die in mitosis while others eventually divide and continue to the next interphase.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationnone givenTTFields frequencies utilized in this series are the specific frequencies that led to highest reduction in cell counts, most likely by virtue of their effect on mitotic spindle.
“TTFields frequencies utilized in this series of investigation are the specific frequencies that have led to the highest reduction in cell counts, most likely by virtue of their effect on the mitotic spindle.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
PremisecitationThe mitotic spindle governs the requisite capturing, alignment, and segregation of chromosomes to two daughter cells.
“The mitotic spindle governs the requisite capturing, alignment, and segregation of chromosomes to two daughter cells1920.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [19] Kline-Smith, S. L. & Walczak, C. E. Mitotic spindle assembly and chromosome segregation: refocusing on microtubule dynamics. Mol. Cell 15, 317–327(2004). source
Not checked in the free run.
- cites [20] Gordon, M. B., Howard, L. & Compton, D. A. Chromosome movement in mitosis requires microtubule anchorage at spindle poles. J. Cell Biol. 152, 425–434 (2001). source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationSenescence, cell death via apoptosis, and continued cell cycling are all possible outcomes of mitotic slippage.
“Senescence, cell death via apoptosis, and continued cell cycling are all possible outcomes of mitotic slippage29.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [29] Yamada, H. Y. & Gorbsky, G. J. Spindle checkpoint function and cellular sensitivity to antimitotic drugs. Mol. Cancer Ther. 5, 2963–2969 (2006). source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThere is inter- and intra-line variation in response to anti-mitotic drugs.
“These observations are in line with growing body of evidence suggesting both inter and intra–line variation in response to anti-mitotic drugs176364.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [17] Gascoigne, K. E. & Taylor, S. S. How do anti-mitotic drugs kill cancer cells? J. Cell Sci. 122, 2579–2585 (2009). source
Not checked in the free run.
- cites [63] Orth, J. D. et al. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol. Cancer Ther. 7, 3480–3489 (2008). source
Not checked in the free run.
- cites [64] Shi, J., Orth, J. D. & Mitchison, T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res. 68, 3269–3276 (2008). source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenAt least 120 cells in metaphase or anaphase were analyzed in each group.
“At least 120 cells in metaphase or anaphase were analyzed in each group.”
Quote in the paperNot a substantial claimMay combine two claims.
Interpretationown dataResults provide first evidence supporting direct effect of TTFields on microtubules, and specific effects on spindle assembly in replicating cells.
“Our results provide the first evidence supporting the direct effect of TTFields on microtubules, and specific effects on spindle assembly in replicating cells.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S2 (checkable). May combine two claims.
InterpretationreasoningData obtained from cell culture studies might advance understanding of in vivo response to TTFields, ultimately enhancing clinical trial designs to improve patient outcomes.
“Therefore, it is likely that data obtained from cell culture studies might indeed advance our understanding of in vivo response to TTFields, ultimately enhancing clinical trial designs to improve patient outcomes.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: The application of TTFields resembles a state in which constant drug concentration is delivered to the tumor.
The authors state this as an assumption.
Electric fields exert directional forces on polar intracellular elements such as organelles and macromolecules.
“A commonality among these hypotheses is the assumption that electric fields exert directional forces on polar intracellular elements such as organelles and macromolecules.”
The authors state this as an assumption.
The progeny of cells that succeeded in completing previous mitosis under TTFields treatment were further damaged on consecutive mitotic events as treatment duration was extended.
“It is reasonable to assume that the progeny of cells which succeeded in completing previous mitosis under TTFields treatment were further damaged on the consecutive mitotic events as the treatment duration was extended.”
The authors state this as an assumption.
The application of TTFields resembles a state in which constant drug concentration is delivered to the tumor.
“In this context, the application of TTFields presumably resembles a state in which constant drug concentration is delivered to the tumor.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TTFields-induced mitotic spindle perturbations lead to abnormal chromosomal segregation, mitotic cell death, and perhaps apoptosis from cells that are able to exit mitosis.
“Such perturbations lead to abnormal chromosomal segregation, mitotic cell death, and perhaps apoptosis from cells that are able to exit mitosis [8,9,19].”
From Permeabilizing Cell Membranes with Electric Fields (2021) · cites this paper as [8]
Dividing cells are affected by TTFields during mitosis.
“Indeed, cellular and pre-clinical studies have demonstrated that dividing cells are affected by TTFields during mitosis [8,37].”
From Permeabilizing Cell Membranes with Electric Fields (2021) · cites this paper as [8]
The standard theory proposes that TTFields disrupt the mitotic spindle in actively dividing cells, leading to aberrant cellular division and eventual cellular death.
“The standard theory proposes a disruption of the mitotic spindle by TTFields in actively dividing cells, thereby leading to aberrant cellular division and eventual cellular death [8,84].”
From Permeabilizing Cell Membranes with Electric Fields (2021) · cites this paper as [8]
The standard theory of how TTFields work requires further elaboration.
“Recent investigations [27] have shown that the standard theory of how TTFields work [8] requires further elaboration.”
From Permeabilizing Cell Membranes with Electric Fields (2021) · cites this paper as [8]
Mitotic disruption by exogenously imposed electric fields has been reported.
“Mitotic disruption by exogenously imposed electric fields have been reported [8]; however, mitotic spindles are not the only biological structures that possess intrinsic dipole moments.”
From Permeabilizing Cell Membranes with Electric Fields (2021) · cites this paper as [8]
PTEN is involved in maintaining mitotic spindle architecture and promoting chromosome alignment and segregation.
“PTEN is involved in maintaining mitotic spindle architecture and promoting chromosome alignment and segregation, functions overlapping with the postulated mechanism of action of TTFields [8,91,92].”
From Permeabilizing Cell Membranes with Electric Fields (2021) · cites this paper as [8]
TTFields induce an anti-mitotic effect by exerting bi-directional forces on highly polar intracellular elements such as tubulin and septin, eliciting abnormal microtubule polymerization during spindle formation and aberrant cleavage furrow formation.
“TTFields were shown to induce an anti-mitotic effect by exerting bi-directional forces on highly polar intracellular elements, such as tubulin and septin molecules, eliciting abnormal microtubule polymerization during spindle formation as well as aberrant cleavage furrow formation.”
From Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Actin Dynamics (2020) · cites this paper as [6]
Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200 kHz) that block cell division and interfere with organelle assembly.
“Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly.”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [10]
The effect of TTFields also results in abnormal chromosomal segregation and reduced clonogenic potential of the cell's progeny.
“This effect also results in abnormal chromosomal segregation and reduced clonogenic potential of the cell’s progeny.10”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [10]
TTFields target proteins with large dipole moments, namely septins and spindle microtubules, which are essential in metaphase and anaphase for separation and equal distribution of chromosomes.
“TTFields will target proteins with large dipole moments (ie, septins and the spindle microtubules, components essential in the metaphase and anaphase stages of the mitotic cycle for separation and equal distribution of chromosomes).9,10”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [10]
The growth inhibitory effect of TTFields is largely mediated by interference on the mitotic spindle apparatus.
“Further studies demonstrated that the growth inhibitory effect is largely mediated by interference on the mitotic spindle apparatus.”
From Tumor treating fields: A novel treatment modality and its use in brain tumors (2016) · cites this paper as [10]
TTFields application leads to abnormal mitosis and aneuploidy in cancer cells.
“TTFields application leads to abnormal mitosis, aneuploidy, and increased cell granularity, which are often associated with enhancement of autophagy.”
From AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields) (2018) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
HeLa treatment frequency falls outside the stated TTFields range
MinorThe HeLa time-lapse experiment says it used 150 Hz TTFields, whereas the paper defines TTFields as operating at 100-300 kHz. The stated experimental frequency is outside that range.
“while exposed to 150 Hz TTFields.”
“TTFields are low-intensity (1–3 V/cm) intermediate-frequency (100–300 kHz), alternating electric fields.”
The claimed field intensity for all studies differs from the rat experiment
MinorThe paper says 175 V/m was used for all studies, but reports applying 200 V/m in the rat experiment.
“Field intensity of 175 V/m was used for all studies”
“TTFields (200 V/m) were applied for 7 days using the optimal frequency of 200 kHz.”
Cites
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1317 · Cited by 4,534 · see citing works
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,025 · see citing works
The spindle-assembly checkpoint in space and time
Musacchio, A., & Salmon, E. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2163 · Cited by 2,227 · see citing works
Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I
Coleman, M. L., Sahai, E. A., Yeo, M., Bosch, M., Dewar, A. L., & Olson, M. F. (2001) · Nature Cell Biology · doi:10.1038/35070009 · Cited by 1,313 · see citing works
Controlling Cell Behavior Electrically: Current Views and Future Potential
McCaig, C., Rajnicek, A. M., Song, B., & Zhao, M. (2005) · Physiological Reviews · doi:10.1152/physrev.00020.2004 · Cited by 1,098 · see citing works
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.
Jordan, M. A., Toso, R. J., Thrower, D., & Wilson, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9552 · Cited by 1,095 · see citing works
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894 · see citing works
Self-citationStupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862 · see citing works
Self-citationBoveri revisited: chromosomal instability, aneuploidy and tumorigenesis
Holland, A. J., & Cleveland, D. W. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2718 · Cited by 859 · see citing works
Mitotic catastrophe: a mechanism for avoiding genomic instability
Vitale, I., Galluzzi, L., Castedo, M., & Kroemer, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3115 · Cited by 834 · see citing works
Disruption of cancer cell replication by alternating electric fields
Kirson, E. D., Gurvich, Z., Schneiderman, R., Dekel, E., Itzhaki, A., Wasserman, Y., Schatzberger, R., & Palti, Y. (2004) · Cancer research · doi:10.1158/0008-5472.can-04-0083 · Cited by 827 · see citing works
Self-citationAneuploidy Acts Both Oncogenically and as a Tumor Suppressor
Weaver, B. A. A., Silk, A. D., Montagna, C., Verdier-Pinard, P., & Cleveland, D. W. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.003 · Cited by 729 · see citing works
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O. D., Koupal, L. R., Liesch, J. M., Goetz, M., Lazarides, E., & Woods, C. M. (1995) · PubMed · Cited by 687 · see citing works
Stuck in Division or Passing through
Rieder, C. L., & Maiato, H. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.09.002 · Cited by 648 · see citing works
Boveri, T. (2007) · Journal of Cell Science · doi:10.1242/jcs.025742 · Cited by 575 · see citing works
Dumontet, C., & Sikic, B. I. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1061 · Cited by 572 · see citing works
The spindle checkpoint: structural insights into dynamic signalling
Musacchio, A., & Hardwick, K. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm929 · Cited by 532 · see citing works
Weaver, B. A. A., & Cleveland, D. W. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.011 · Cited by 523 · see citing works
Proliferation of aneuploid human cells is limited by a p53-dependent mechanism
Thompson, S. L., & Compton, D. A. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200905057 · Cited by 494 · see citing works
Belmont, L. D., Hyman, A. A., Sawin, K. E., & Mitchison, T. J. (1990) · Cell · doi:10.1016/0092-8674(90)90022-7 · Cited by 443 · see citing works
Zasadil, L. M., Andersen, K. A., Yeum, D., Rocque, G. B., Wilke, L. G., Tevaarwerk, A. J., Raines, R. T., Burkard, M. E., & Weaver, B. A. A. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007965 · Cited by 403 · see citing works
How do anti-mitotic drugs kill cancer cells?
Gascoigne, K. E., & Taylor, S. S. (2009) · Journal of Cell Science · doi:10.1242/jcs.039719 · Cited by 375 · see citing works
Gene Copy-Number Alterations: A Cost-Benefit Analysis
Tang, Y.-C., & Amon, A. (2013) · Cell · doi:10.1016/j.cell.2012.11.043 · Cited by 348 · see citing works
Mitotic Spindle Assembly and Chromosome Segregation
Kline-Smith, S. L., & Walczak, C. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.07.012 · Cited by 295 · see citing works
Evidence that Mitotic Exit Is a Better Cancer Therapeutic Target Than Spindle Assembly
Huang, H.-C., Shi, J., Orth, J. D., & Mitchison, T. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.020 · Cited by 290 · see citing works
The ATM–p53 pathway suppresses aneuploidy-induced tumorigenesis
Li, M., Fang, X., Baker, D. J., Guo, L., Gao, X., Wei, Z., Han, S., van Deursen, J. M., & Zhang, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005960107 · Cited by 257 · see citing works
Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors
Silk, A. D., Zasadil, L. M., Holland, A., Vitre, B., Cleveland, D., & Weaver, B. A. (2013) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1317042110 · Cited by 256 · see citing works
Ahmed, A. A., Mills, A. D., Ibrahim, A. E. K., Temple, J., Blenkiron, C., Vias, M., Massie, C. E., Iyer, N. G., McGeoch, A. T., Crawford, R., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.014 · Cited by 233 · see citing works
Cell Type Variation in Responses to Antimitotic Drugs that Target Microtubules and Kinesin-5
Shi, J., Orth, J. D., & Mitchison, T. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6699 · Cited by 231 · see citing works
Kirson, E. D., Schneiderman, R. S., Dbalý, V., Tovaryš, F., Vymazal, J., Itzhaki, A., Mordechovich, D., Gurvich, Z., Shmueli, E., Goldsher, D., et al. (2009) · BMC Medical Physics · doi:10.1186/1756-6649-9-1 · Cited by 224 · see citing works
Self-citationCoupling cell division and cell death to microtubule dynamics
Sorger, P. K., Dobles, M., Tournebize, R., & Hyman, A. A. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80081-6 · Cited by 222 · see citing works
Yoon, S.-O., Shin, S., & Mercurio, A. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4122 · Cited by 221 · see citing works
Microtubule dynamics: taking aim at a moving target
Wilson, L., & Jordan, M. A. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90119-1 · Cited by 213 · see citing works
Tumor treating fields: A new frontier in cancer therapy
Davies, A. M., Weinberg, U., & Palti, Y. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12112 · Cited by 193 · see citing works
Self-citationUnderstanding and controlling the cell cycle with natural products
Hung, D. T., Jamison, T. F., & Schreiber, S. L. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90129-5 · Cited by 183 · see citing works
Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells
Li, R., Yerganian, G., DUESBERG, P. H., Kraemer, A., Willer, A., Rausch, C., & Hehlmann, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14506 · Cited by 172 · see citing works
Elhajouji, A., Cunha, M., & Kirsch‐Volders, M. (1998) · Mutagenesis · doi:10.1093/mutage/13.2.193 · Cited by 163 · see citing works
Detection and characterization of mechanisms of action of aneugenic chemicals
Parry, E. M. (2002) · Mutagenesis · doi:10.1093/mutage/17.6.509 · Cited by 153 · see citing works
Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.010 · Cited by 152 · see citing works
Debate Surges Over the Origins of Genomic Defects in Cancer
Marx, J. L. (2002) · Science · doi:10.1126/science.297.5581.544 · Cited by 151 · see citing works
The Role of Microtubules and Their Dynamics in Cell Migration
Ganguly, A., Yang, H., Sharma, R. S., Patel, K. D., & Cabral, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.423905 · Cited by 145 · see citing works
Mattei, M. D., Caruso, A., TRAINA, G. C., Pezzetti, F., Baroni, T., & Sollazzo, V. (1999) · Bioelectromagnetics · doi:10.1002/(sici)1521-186x(1999)20:3 · Cited by 142 · see citing works
Electric field generated by axial longitudinal vibration modes of microtubule
Cifra, M., Pokorný, J., Havelka, D., & Kučera, O. (2010) · Biosystems · doi:10.1016/j.biosystems.2010.02.007 · Cited by 137 · see citing works
Giladi, M., Weinberg, U., Schneiderman, R. S., Porat, Y., Munster, M., Voloshin, T., Blatt, R., Cahal, S., Itzhaki, A., Onn, A., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.006 · Cited by 132 · see citing works
Self-citationPredicting the electric field distribution in the brain for the treatment of glioblastoma
Miranda, P. C., Mekonnen, A., Salvador, R., & Basser, P. J. (2014) · Physics in Medicine and Biology · doi:10.1088/0031-9155/59/15/4137 · Cited by 131 · see citing works
Predictive factors for response to docetaxel in human breast cancers
Noguchi, S. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00265.x · Cited by 127 · see citing works
Chromosome Movement in Mitosis Requires Microtubule Anchorage at Spindle Poles
Gordon, M. B., Howard, L., & Compton, D. A. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.3.425 · Cited by 123 · see citing works
Orth, J. D., Tang, Y., Shi, J., Loy, C. T., Amendt, C., Wilm, C., Zenke, F. T., & Mitchison, T. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0684 · Cited by 119 · see citing works
Vignon, C., Debeissat, C., Georget, M., Bouscary, D., Gyan, E., Rosset, P., & Hérault, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068425 · Cited by 111 · see citing works
Pless, M., Droege, C., von Moos, R., Salzberg, M. O., & Betticher, D. C. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.06.025 · Cited by 108 · see citing works
Demidenko, Z. N., Kalurupalle, S., Hanko, C., Lim, C.-U., Broude, E. V., & Blagosklonny, M. V. (2008) · Oncogene · doi:10.1038/onc.2008.82 · Cited by 100 · see citing works
Giladi, M., Schneiderman, R. S., Porat, Y., Munster, M., Itzhaki, A., Mordechovich, D., Cahal, S., Kirson, E. D., Weinberg, U., & Palti, Y. (2014) · Pancreatology · doi:10.1016/j.pan.2013.11.009 · Cited by 98 · see citing works
Self-citationSpindle checkpoint function and cellular sensitivity to antimitotic drugs
Yamada, H. Y., & Gorbsky, G. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0319 · Cited by 94 · see citing works
High-frequency electric field and radiation characteristics of cellular microtubule network
Havelka, D., Cifra, M., Kučera, O., Pokorný, J., & Vrba, J. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2011.07.007 · Cited by 92 · see citing works
The use of electric fields in tissue engineering: A review
Markx, G. H. (2008) · Organogenesis · doi:10.4161/org.5799 · Cited by 92 · see citing works
Chu, S. W. L., Badar, S., Morris, D. L., & Pourgholami, M. H. (2009) · PubMed · Cited by 73 · see citing works
Bassett, C. A. L. (1985) · Clinics in Plastic Surgery · doi:10.1016/s0094-1298(20)31696-5 · Cited by 60 · see citing works
Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer
Acuña, L. R., Langhi, M., Pérez, J., Acuña, J. R., Machiavelli, M., Lacava, J., Vallejo, C., Romero, A., Fasce, H., Ortiz, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.74 · Cited by 54 · see citing works
Extracellular matrix controls tubulin monomer levels in hepatocytes by regulating protein turnover.
Mooney, D. J., Hansen, L. K., Langer, R., Vacanti, J. P., & Ingber, D. E. (1994) · Molecular Biology of the Cell · doi:10.1091/mbc.5.12.1281 · Cited by 53 · see citing works
Pearson, C. G., Gardner, M. K., Paliulis, L. V., Salmon, E. D., Odde, D. J., & Bloom, K. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-04-0312 · Cited by 45 · see citing works
Sun, Z., Xiao, B., Jha, H. C., Lu, J. L., Banerjee, S., & Robertson, E. S. (2014) · Journal of Virology · doi:10.1128/jvi.00554-14 · Cited by 38 · see citing works
Turner, S., Gergel, T., Wu, H., Lacroix, M., & Toms, S. A. (2014) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-12-162 · Cited by 35 · see citing works
An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas
Wong, E. T., Lok, E., & Swanson, K. D. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0353-5 · Cited by 35 · see citing works
Hong, F. (1999) · Carcinogenesis · doi:10.1093/carcin/20.7.1161 · Cited by 31 · see citing works
Sihn, C., Suh, E., Lee, K.-H., Kim, T.-Y., & Kim, S. H. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00465-8 · Cited by 29 · see citing works
Comparison of iodotyrosines and methionine uptake in a rat glioma model.
Langen, K., Clauss, R. P., Holschbach, M. H., Mühlensiepen, H., Kiwit, J. C. W., Zilles, K., Coenen, H. H., & Müller-Gärtner, H.-W. (1998) · PubMed · Cited by 24 · see citing works
Saini, M., Bellinzona, M., Meyer, F., Calı̀, G., & Samii, M. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006128825766 · Cited by 20 · see citing works
Signal and Noise Modeling in Confocal Laser Scanning Fluorescence Microscopy
Herberich, G., Windoffer, R., Leube, R. E., & Aach, T. (2012) · Lecture notes in computer science · doi:10.1007/978-3-642-33415-3_47 · Cited by 13 · see citing works
Orticello, M., Fiore, M., Totta, P., Desideri, M., Barisic, M., Passeri, D., Lenzi, J., Rosa, A., Orlandi, A., Maiato, H., et al. (2015) · Oncogene · doi:10.1038/onc.2014.265 · Cited by 12 · see citing works
Flagged first, then by citations
1 of the 70 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Elson, E. Biologic effects of radiofrequency and microwave fields: in vivo and in vitro experimental results in The biomedical engineering handbook (ed. Bronzino, J. D. ) 1417–1423 (CRC Press, 1995).
Cited by
Sorted by citations
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644 · see citing works
Self-citationTumor-Treating Fields: A Fourth Modality in Cancer Treatment
Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1117 · Cited by 380 · see citing works
Self-citationTumour treating fields therapy for glioblastoma: current advances and future directions
Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C. H., Al-Tamimi, Y., & Collis, S. J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01136-5 · Cited by 319 · see citing works
Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives
Seker-Polat, F., Degirmenci, N. P., Solaroğlu, İ., & Onder, T. B. (2022) · Cancers · doi:10.3390/cancers14020443 · Cited by 261 · see citing works
TAPHOORN, M. J. B., Dirven, L., Kanner, A. A., Lavy-Shahaf, G., Weinberg, U., Taillibert, S., Toms, S. A., Honnorat, J., Chen, T. C., Šroubek, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5082 · Cited by 201 · see citing works
Self-citationToms, S. A., Kim, C., Nicholas, G. A., & Ram, Z. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03057-z · Cited by 183 · see citing works
Voloshin, T., Kaynan, N., Davidi, S., Porat, Y., Shteingauz, A., Schneiderman, R. S., Zeevi, E., Munster, M., Blat, R., Tempel-Brami, C., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02534-7 · Cited by 182 · see citing works
Self-citationTumor treating fields: A novel treatment modality and its use in brain tumors
Hottinger, A. F., Pacheco, P., & Stupp, R. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now182 · Cited by 177 · see citing works
Ceresoli, G. L., Aerts, J. G., Dziadziuszko, R., Ramlau, R., Cedres, S., van Meerbeeck, J. P., Mencoboni, M., Planchard, D., Chella, A., Crinò, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30532-7 · Cited by 164 · see citing works
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death
Asadzadeh, Z., Safarzadeh, E., Safaei, S., Baradaran, A., Mohammadi, A., Hajiasgharzadeh, K., Derakhshani, A., Argentiero, A., Silvestris, N., & Baradaran, B. (2020) · Cancers · doi:10.3390/cancers12041047 · Cited by 157 · see citing works
Chen, D., Le, S. B., Hutchinson, T. E., Calinescu, A.-A., Sebastian, M., Jin, D., Liu, T., Ghiaseddin, A. P., Rahman, M., & Tran, D. D. (2022) · Journal of Clinical Investigation · doi:10.1172/jci149258 · Cited by 152 · see citing works
Neuromodulation techniques – From non-invasive brain stimulation to deep brain stimulation
Davidson, B., Bhattacharya, A., Sarica, C., Darmani, G., Raies, N., Chen, R. E., & Lozano, A. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00330 · Cited by 151 · see citing works
Tumor treating fields increases membrane permeability in glioblastoma cells
Chang, E., Patel, C. B., Pohling, C., Young, C., Song, J., Flores, T. A., Zeng, Y., Joubert, L.-M., Arami, H., Natarajan, A., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0130-x · Cited by 137 · see citing works
Karanam, N. K., Kalayarasan, S., Ding, L., Sishc, B. J., Saha, D., & Story, M. D. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.136 · Cited by 136 · see citing works
Wenger, C., Miranda, P. C., Salvador, R., Thielscher, A., Bomzon, Z., Giladi, M., Mrugala, M. M., & Korshoej, A. R. (2018) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2017.2765282 · Cited by 129 · see citing works
Self-citationBallo, M. T., Urman, N., Lavy-Shahaf, G., Grewal, J., Bomzon, Z., & Toms, S. A. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.04.008 · Cited by 128 · see citing works
Self-citationThe Mechanisms of Action of Tumor Treating Fields
Moser, J. C., Salvador, E., Deniz, K., Swanson, K. D., Tuszyński, J. A., Carlson, K. W., Karanam, N. K., Patel, C. B., Story, M. D., Lou, E., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0887 · Cited by 117 · see citing works
Biological activity of tumor-treating fields in preclinical glioma models
Silginer, M., Weller, M., Stupp, R., & Roth, P. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.171 · Cited by 111 · see citing works
Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions
Li, T., Li, J., Chen, Z., Zhang, S., Li, S., Wageh, S., Al‐Hartomy, O. A., Al-Sehemi, A. G., Xie, Z., Kankala, R. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.065 · Cited by 110 · see citing works
Shteingauz, A., Porat, Y., Voloshin, T., Schneiderman, R. S., Munster, M., Zeevi, E., Kaynan, N., Gotlib, K., Giladi, M., Kirson, E. D., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1085-9 · Cited by 107 · see citing works
Self-citationVoloshin, T., Schneiderman, R. S., Volodin, A., Shamir, R. R., Kaynan, N., Zeevi, E., Koren, L., Klein-Goldberg, A., Paz, R., Giladi, M., et al. (2020) · Cancers · doi:10.3390/cancers12103016 · Cited by 94 · see citing works
Self-citationRivera, F., Benavides, M., Gallego-Plazas, J., Guillén‐Ponce, C., Lopez-Martin, J. A., & Küng, M. (2018) · Pancreatology · doi:10.1016/j.pan.2018.10.004 · Cited by 89 · see citing works
Berkelmann, L., Bader, A., Meshksar, S., Dierks, A., Majernik, G. H., Krauss, J. K., Schwabe, K., Manteuffel, D., & Ngezahayo, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-43621-9 · Cited by 81 · see citing works
Radiotherapy in Glioblastoma: the Past, the Present and the Future
Gzell, C., Back, M., Wheeler, H., Bailey, D. L., & Foote, M. C. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.09.015 · Cited by 78 · see citing works
Vergote, I. B., von Moos, R., Manso, L., Nieuwenhuysen, E. V., Concin, N., & Sessa, C. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.018 · Cited by 78 · see citing works
Interactions between electromagnetic radiation and biological systems
Liu, L., Huang, B., Lu, Y., Zhao, Y., Tang, X., & Shi, Y. (2024) · iScience · doi:10.1016/j.isci.2024.109201 · Cited by 80 · see citing works
Voloshin, T., Munster, M., Blatt, R., Shteingauz, A., Roberts, P. C., Schmelz, E. M., Giladi, M., Schneiderman, R. S., Zeevi, E., Porat, Y., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30406 · Cited by 77 · see citing works
Self-citationPermeabilizing Cell Membranes with Electric Fields
Aguilar, A. A., Ho, M. C., Chang, E., Carlson, K. W., Natarajan, A., Marciano, T., Bomzon, Z., & Patel, C. B. (2021) · Cancers · doi:10.3390/cancers13092283 · Cited by 76 · see citing works
Self-citationTumor-Treating Fields in Glioblastomas: Past, Present, and Future
Guo, X., Yang, X., Wu, J., Yang, H., Li, Y., Li, J., Liu, Q., Chen, W., Xing, H., Liu, P., et al. (2022) · Cancers · doi:10.3390/cancers14153669 · Cited by 73 · see citing works
Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma
Low, J., Brown, M. C., Reitman, Z. J., Bernstock, J. D., Markert, J. M., Friedman, G. K., Waitkus, M. S., Bowie, M. L., & Ashley, D. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci163452 · Cited by 73 · see citing works
Korshoej, A. R., Hansen, F. L., Thielscher, A., von Öettingen, G., & Sørensen, J. C. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179214 · Cited by 71 · see citing works
Zvi Ram on behalf of the EF-14 Trial Investigators, Zhu, J., Demireva, P., Kanner, A. A., Pannullo, S. C., Mehdorn, H. M., Avgeropoulos, N. G., Salmaggi, A., Silvani, A., Goldlust, S. A., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2601-y · Cited by 71 · see citing works
Lacouture, M. E., Anadkat, M. J., Ballo, M. T., IWAMOTO, F. M., Jeyapalan, S. A., Rocca, R. V. L., Schwartz, M. A., Serventi, J. N., & Glas, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01045 · Cited by 70 · see citing works
Electrotherapies for Glioblastoma
Jenkins, E. P. W., Finch, A., Gerigk, M., Triantis, I. F., Watts, C., & Malliaras, G. G. (2021) · Advanced Science · doi:10.1002/advs.202100978 · Cited by 68 · see citing works
Emerging medical applications based on non-ionizing electromagnetic fields from 0 Hz to 10 THz
Mattsson, M., & Simkó, M. (2019) · Medical Devices Evidence and Research · doi:10.2147/mder.s214152 · Cited by 67 · see citing works
Tumor treating fields for high-grade gliomas
Luo, C., Xu, S., Dai, G., Xiao, Z., Chen, L., & Liu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110193 · Cited by 67 · see citing works
Mittal, S., Klinger, N. V., Michelhaugh, S. K., Barger, G. R., Pannullo, S. C., & Juhász, C. (2017) · Journal of neurosurgery · doi:10.3171/2016.9.jns16452 · Cited by 66 · see citing works
Kessler, A. F., Frömbling, G. E., Gross, F., Hahn, M., Dzokou, W., Ernestus, R.-I., Löhr, M., & Hagemann, C. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0079-9 · Cited by 64 · see citing works
Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells
Neuhaus, E., Zirjacks, L., Ganser, K., Klumpp, L., Schüler, U., Zips, D., Eckert, F., & Huber, S. M. (2019) · Cancers · doi:10.3390/cancers11010110 · Cited by 63 · see citing works
Stewart, T. S.-J., Nagesetti, A., Guduru, R., Liang, P., Stimphil, E., Hadjikhani, A., Salgueiro, L., Horstmyer, J., Cai, R., Schally, A. V., et al. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0300 · Cited by 63 · see citing works
Porat, Y., Giladi, M., Schneiderman, R. S., Blat, R., Shteingauz, A., Zeevi, E., Munster, M., Voloshin, T., Kaynan, N., Tal, O., et al. (2017) · Journal of Visualized Experiments · doi:10.3791/55820 · Cited by 65 · see citing works
Self-citationJo, Y., Kim, E. H., Sai, S., Kim, J. S., Cho, J.-M., Kim, H., Baek, J., Kim, J., Hwang, S., & Yoon, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113684 · Cited by 62 · see citing works
Shi, W., Blumenthal, D. T., Oberheim Bush, N. A., Kebir, S., Lukas, R. V., Muragaki, Y., Zhu, J.-J., & Glas, M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03540-6 · Cited by 61 · see citing works
Li, X., Yang, F., & Rubinsky, B. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.2965883 · Cited by 59 · see citing works
Tanzhu, G., Chen, L., Xiao, G., Shi, W., Peng, H., Chen, D., & Zhou, R. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01206-y · Cited by 60 · see citing works
The distinguishing electrical properties of cancer cells
Gregorio, E. D., Israel, S. L., Staelens, M., Tankel, G., Shankar, K., & Tuszyński, J. A. (2022) · Physics of Life Reviews · doi:10.1016/j.plrev.2022.09.003 · Cited by 57 · see citing works
Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma
Khagi, S., Kotecha, R. R., Gatson, N. T., Jeyapalan, S. A., Abdullah, H. I., Avgeropoulos, N. G., Batzianouli, E., Giladi, M., Lustgarten, L., & Goldlust, S. A. (2024) · The Oncologist · doi:10.1093/oncolo/oyae227 · Cited by 56 · see citing works
Self-citationKaranam, N. K., & Story, M. D. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1837984 · Cited by 56 · see citing works
Toward Hijacking Bioelectricity in Cancer to Develop New Bioelectronic Medicine
Robinson, A. J., Jain, A., Sherman, H. G., Hague, R., Rahman, R., Sanjuan‐Alberte, P., & Rawson, F. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000248 · Cited by 54 · see citing works
Tumor treating fields: a new approach to glioblastoma therapy
Rick, J. W., Chandra, A., & Aghi, M. K. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2768-x · Cited by 52 · see citing works
All Wired Up: An Exploration of the Electrical Properties of Microtubules and Tubulin
Kalra, A. P., Eakins, B. B., Patel, S. D., Ciniero, G., Rezania, V., Shankar, K., & Tuszynski, J. A. (2020) · ACS Nano · doi:10.1021/acsnano.0c06945 · Cited by 49 · see citing works
Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment
Carrieri, F. A., Smack, C., Siddiqui, I., Kleinberg, L. R., & Tran, P. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.575992 · Cited by 50 · see citing works
Mumblat, Y., Martinez-Conde, A., Braten, O., Munster, M., Dor-On, E., Schneiderman, R. S., Porat, Y., Voloshin, T., Davidi, S., Blatt, R., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.011 · Cited by 50 · see citing works
Self-citationThe Impact of Tumor Treating Fields on Glioblastoma Progression Patterns
Glas, M., Ballo, M. T., Bomzon, Z., Urman, N., Levi, S., Lavy-Shahaf, G., Jeyapalan, S. A., Sio, T. T. W., DeRose, P. M., Misch, M., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.12.152 · Cited by 48 · see citing works
Self-citationTrusheim, J. E., Dunbar, E. M., Battiste, J. D., IWAMOTO, F. M., Mohile, N. A., Damek, D., Bota, D. A., & Connelly, J. (2016) · CNS Oncology · doi:10.2217/cns-2016-0032 · Cited by 48 · see citing works
Lee, Y., Seo, H. W., Baek, J.-H., Lim, S. H., Hwang, S., & Kim, E. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-68473-6 · Cited by 48 · see citing works
Sharpe, M. A., Baskin, D. S., Pichumani, K., Ijare, O. B., & Helekar, S. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.768758 · Cited by 47 · see citing works
Salvador, E., Kessler, A. F., Domröse, D., Hörmann, J., Schaeffer, C. M., Giniunaite, A., Burek, M., Tempel-Brami, C., Voloshin, T., Volodin, A., et al. (2022) · Biomolecules · doi:10.3390/biom12101348 · Cited by 47 · see citing works
Self-citationClark, P. A., Gaal, J. T., Strebe, J. K., Pasch, C. A., Deming, D. A., Kuo, J. S., & Robins, H. I. (2016) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2016.10.042 · Cited by 46 · see citing works
Kaina, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237442 · Cited by 45 · see citing works
Yoon, Y. N., Lee, D.-S., Park, H. J., & Kim, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-59445-x · Cited by 44 · see citing works
Ion Channels as Therapeutic Targets in High Grade Gliomas
Griffin, M., Khan, R. N., Basu, S., & Smith, S. J. (2020) · Cancers · doi:10.3390/cancers12103068 · Cited by 44 · see citing works
Glioma invasion along white matter tracts: A dilemma for neurosurgeons
Wang, J., Liang, Y., Kang, Q., Zhou, J. Y., Chen, T.-Q., Hugnot, J., & Yu, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.11.020 · Cited by 43 · see citing works
Li, X., Liu, K., Xing, L., & Rubinsky, B. (2023) · Radiology and Oncology · doi:10.2478/raon-2023-0044 · Cited by 42 · see citing works
Benson, L. M. (2018) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2018.03.005 · Cited by 41 · see citing works
Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields
Chang, E., Pohling, C., Beygui, N., Patel, C. B., Rosenberg, J., Ha, D. H., & Gambhir, S. S. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2534-5 · Cited by 39 · see citing works
Dono, A., Mitra, S., Shah, M., Takayasu, T., Zhu, J., Tandon, N., Patel, C. B., Esquenazi, Y., & Ballester, L. Y. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03755-1 · Cited by 39 · see citing works
Ram, Z., Kim, C., Hottinger, A. F., Idbaïh, A., Nicholas, G. A., & Zhu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671972 · Cited by 37 · see citing works
Tumor-Treating Fields Induce RAW264.7 Macrophage Activation Via NK-κB/MAPK Signaling Pathways
Park, J., Song, K., Jung, S.-Y., Ahn, J., Hwang, S., Kim, J., Kim, E. H., & Song, J. Y. (2019) · Technology in Cancer Research & Treatment · doi:10.1177/1533033819868225 · Cited by 37 · see citing works
Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates
Arvind, R., Chandana, S. R., Borad, M. J., Pennington, D., Mody, K., & Babiker, H. M. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103535 · Cited by 38 · see citing works
Tumor treating fields: a comprehensive overview of the underlying molecular mechanism
Hong, P., Kudulaiti, N., Wu, S., Nie, J., & Zhuang, D. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2017283 · Cited by 34 · see citing works
Davidi, S., Jacobovitch, S., Shteingauz, A., Martinez-Conde, A., Braten, O., Tempel-Brami, C., Zeevi, E., Frechtel-Gerzi, R., Ene, H. M., Dor-On, E., et al. (2022) · Cancers · doi:10.3390/cancers14122959 · Cited by 35 · see citing works
Self-citationTumour treating fields in a combinational therapeutic approach
Branter, J., Basu, S., & Smith, S. J. (2018) · Oncotarget · doi:10.18632/oncotarget.26344 · Cited by 35 · see citing works
Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis
Regev, O., Merkin, V., Blumenthal, D. T., Melamed, I., & Kaisman‐Elbaz, T. (2021) · Neuro-Oncology Practice · doi:10.1093/nop/npab026 · Cited by 34 · see citing works
Campana, L. G., DAUD, A. I., Lancellotti, F., Arroyo, J. P., Davalos, R. V., Prata, C. D., & Gehl, J. (2023) · Cancers · doi:10.3390/cancers15133340 · Cited by 33 · see citing works
Hershkovich, H. S., Urman, N., Yesharim, O., Naveh, A., & Bomzon, Z. (2019) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab33c6 · Cited by 32 · see citing works
Self-citationIn Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso
Blatt, R., Davidi, S., Munster, M., Shteingauz, A., Cahal, S., Zeidan, A., Marciano, T., Bomzon, Z., Haber, A., Giladi, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670809 · Cited by 32 · see citing works
Self-citationFishman, H., Monin, R., Dor-On, E., Kinzel, A., Haber, A., Giladi, M., Weinberg, U., & Palti, Y. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04308-4 · Cited by 33 · see citing works
Self-citationWang, Y., Pandey, M. K., & Ballo, M. T. (2019) · The Oncologist · doi:10.1634/theoncologist.2017-0603 · Cited by 31 · see citing works
Guberina, N., Pöttgen, C., Kebir, S., Lazaridis, L., Scharmberg, C., Lübcke, W., Niessen, M., Guberina, M., Scheffler, B., Jendrossek, V., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01521-7 · Cited by 31 · see citing works
Gentilal, N., & Miranda, P. C. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105706 · Cited by 31 · see citing works
Novel facets of glioma invasion
Fabian, C., Han, M., Bjerkvig, R., & Niclou, S. P. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.08.001 · Cited by 31 · see citing works
Shams, S., & Patel, C. B. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac047 · Cited by 30 · see citing works
Reversing the Tumor Target: Establishment of a Tumor Trap
Najberg, M., Mansor, M. H., Boury, F., Alvarez‐Lorenzo, C., & Garcion, E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00887 · Cited by 30 · see citing works
Jin, X., Wang, J., Zou, S., Xu, R., Cao, J., Zhang, Y., Guo, J., Wen, X., Deng, S., Zheng, Y., et al. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x20500330 · Cited by 31 · see citing works
Selective toxicity of tumor treating fields to melanoma: an in vitro and in vivo study
Jo, Y., Hwang, S., Jin, Y. B., Sung, J., Jeong, Y. K., Baek, J. H., Cho, J.-M., Kim, E. H., & Yoon, M. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0106-x · Cited by 29 · see citing works
Investigation of the Electrical Properties of Microtubule Ensembles under Cell-Like Conditions
Kalra, A. P., Patel, S., Bhuiyan, A., Preto, J., Scheuer, K. G., Mohammed, U., Lewis, J. D., Rezania, V., Shankar, K., & Tuszyński, J. A. (2020) · Nanomaterials · doi:10.3390/nano10020265 · Cited by 29 · see citing works
Gkika, E., Grosu, A., Macarulla, T. M., Gracián, A. C., Brunner, T. B., Schultheiß, M., Pazgan−Simon, M., Seufferlein, T. T. W., & Touchefeu, Y. (2022) · Cancers · doi:10.3390/cancers14061568 · Cited by 29 · see citing works
Pohling, C., Nguyen, H., Chang, E., Schubert, K. E., Nie, Y., Bashkirov, V. A., Yamamoto, V. N., Zeng, Y., Stupp, R., Schulte, R. W., et al. (2022) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2022.108287 · Cited by 28 · see citing works
Zhong, S., Yao, S., Zhao, Q., Wang, Z., Liu, Z., Li, L., & Wang, Z. L. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200143 · Cited by 28 · see citing works
Modified carbazoles destabilize microtubules and kill glioblastoma multiform cells
Diaz, P., Horne, E. A., Xu, C., Hamel, E., Wagenbach, M., Petrov, R. R., Uhlenbruck, B. J. H., Haas, B. R., Hothi, P., Wordeman, L. G., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.026 · Cited by 28 · see citing works
Liu, S., Zhao, Q., Shi, W., Zheng, Z., Liu, Z., Meng, L., Dong, L., & Jiang, X. M. (2020) · Journal of Cancer · doi:10.7150/jca.51107 · Cited by 27 · see citing works
Temperature control in TTFields therapy of GBM: impact on the duty cycle and tissue temperature
Gentilal, N., Salvador, R., & Miranda, P. C. (2019) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab5323 · Cited by 27 · see citing works
Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields)
Klein-Goldberg, A., Voloshin, T., Tov, E. Z., Paz, R., Somri-Gannam, L., Volodin, A., Koren, L., Lifshitz, L., Meir, A., Shabtay‐Orbach, A., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07546-8 · Cited by 26 · see citing works
Self-citationSalvador, E., Koeppl, T., Hörmann, J., Schönhärl, S., Bugaeva, P., Kessler, A. F., Burek, M., Ernestus, R., Löhr, M., & Hagemann, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010185 · Cited by 26 · see citing works
Patel, C. B., Beinat, C., Xie, Y., Chang, E., & Gambhir, S. S. (2020) · Neoplasia · doi:10.1016/j.neo.2020.11.003 · Cited by 26 · see citing works
Porat, Y., Giladi, M., Schneiderman, R. S., Blat, R., Shteingauz, A., Zeevi, E., Munster, M., Voloshin, T., Kaynan, N., Tal, O., et al. (2017) · Journal of Visualized Experiments · doi:10.3791/55820-v · Cited by 25 · see citing works
Self-citationChen, C., Xu, H., Song, K., Zhang, Y., Zhang, J., Wang, Y., Sheng, X., Chen, L., & Qin, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195855 · Cited by 25 · see citing works
Dahlgren, P. N., Bishop, K., Dey, S., Herbert, B., & Tanaka, H. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.007 · Cited by 25 · see citing works
Bioelectronic medicines: Therapeutic potential and advancements in next-generation cancer therapy
Singh, A. K., Awasthi, R., & Malviya, R. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188808 · Cited by 24 · see citing works
- Authors
- Giladi, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Munster, M., Blat, R., Sherbo, S., Bomzon, Z., Urman, N., Itzhaki, A., Cahal, S., Shteingauz, A., Chaudhry, A., Kirson, E. D., Weinberg, U., & Palti, Y.
- Corresponding author
- Giladi, Moshe
- Venue
- Scientific Reports
- Published
- 2015-12-11
- Volume
- 5
- Issue
- 1
- Pages
- 18046-18046
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4676010
- OpenAlex
- W2196065821
- Cited by
- 327
- References
- 70
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 32 · 2023: 40 · 2022: 47 · 2021: 34 · 2020: 34 · 2019: 27 · 2018: 28 · 2017: 15 · 2016: 11
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Electromagnetic Fields and Biological Effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Microbial Inactivation Methods
- Keywords
- tumor treating fields, AC electric field, mitotic spindle disruption, microtubule assembly, tubulin, chromosome segregation, mitotic catastrophe, multinucleation, caspase-dependent apoptosis, clonogenic survival, cell division rate, tumor cell viability
- MeSH terms
- Animals, Cell Survival, Electricity, Humans, Microtubules, Mitosis, Spindle Apparatus, Neoplasms, Rats, Inbred F344, Tubulin, Apoptosis, Chromosome Segregation, Cell Line, Tumor, Rats, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review